Dynavax Initiates Phase 1/2 Study of Novel Shingles Vaccine Program

EMERYVILLE, Calif., June 27, 2024 /PRNewswire/ — Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the first participant has been dosed in a Phase 1/2 clinical trial…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

ADVERTISEMENT — Advertise With Biotech Networks